These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 17481639

  • 1. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
    Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K.
    Atherosclerosis; 2008 Jan; 196(1):172-179. PubMed ID: 17481639
    [Abstract] [Full Text] [Related]

  • 2. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
    Nakano K, Egashira K, Tada H, Kohjimoto Y, Hirouchi Y, Kitajima S, Endo Y, Li XH, Sunagawa K.
    J Hypertens; 2006 Sep; 24(9):1881-9. PubMed ID: 16915039
    [Abstract] [Full Text] [Related]

  • 3. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M.
    Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
    [Abstract] [Full Text] [Related]

  • 4. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
    Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M.
    J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
    [Abstract] [Full Text] [Related]

  • 5. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
    Kurobe H, Matsuoka Y, Hirata Y, Sugasawa N, Maxfield MW, Sata M, Kitagawa T.
    J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1501-8. PubMed ID: 23535154
    [Abstract] [Full Text] [Related]

  • 6. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
    Noda K, Hosoya M, Nakajima S, Ohashi J, Fukumoto Y, Shimokawa H.
    Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
    [Abstract] [Full Text] [Related]

  • 7. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
    Fujisawa M, Yorikane R, Chiba S, Koike H.
    J Cardiovasc Pharmacol; 2009 Apr; 53(4):325-32. PubMed ID: 19295444
    [Abstract] [Full Text] [Related]

  • 8. The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
    Fujisawa M, Yorikane R, Matsuoka Y, Koike H, Ueno K.
    J Cardiovasc Pharmacol; 2013 Jan; 61(1):63-9. PubMed ID: 23288106
    [Abstract] [Full Text] [Related]

  • 9. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.
    Komoda H, Inoue T, Node K.
    Clin Exp Hypertens; 2010 Jan; 32(2):121-8. PubMed ID: 20374186
    [Abstract] [Full Text] [Related]

  • 10. Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
    Matsui T, Yamagishi S, Nakamura K, Inoue H.
    J Int Med Res; 2006 Jan; 34(6):671-5. PubMed ID: 17295000
    [Abstract] [Full Text] [Related]

  • 11. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
    Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, Sehara Y, Deguchi K, Yamashita T, Abe K.
    Brain Res; 2007 Oct 24; 1176():143-50. PubMed ID: 17904110
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
    Inomata J, Murai H, Kaneko S, Hamaoka T, Ikeda T, Kobayashi D, Usui S, Furusho H, Sugiyama Y, Takata S, Takamura M.
    J Hypertens; 2014 Sep 24; 32(9):1898-904. PubMed ID: 24979307
    [Abstract] [Full Text] [Related]

  • 13. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
    Nagasu H, Satoh M, Fujimoto S, Tomita N, Sasaki T, Kashihara N.
    Hypertens Res; 2012 Mar 24; 35(3):348-55. PubMed ID: 22072106
    [Abstract] [Full Text] [Related]

  • 14. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.
    Ma J, Kishida S, Wang GQ, Meguro K, Imuta H, Oonuma H, Iida H, Jo T, Takano H, Morita T, Nagai R, Nakajima T.
    J Cardiovasc Pharmacol; 2006 Feb 24; 47(2):314-21. PubMed ID: 16495772
    [Abstract] [Full Text] [Related]

  • 15. In vivo imaging of renal redox status during azelnidipine treatment.
    Hirayama A, Ueda A, Oteki T, Nagase S, Aoyagi K, Koyama A.
    Hypertens Res; 2008 Aug 24; 31(8):1643-50. PubMed ID: 18971540
    [Abstract] [Full Text] [Related]

  • 16. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
    Nakamoto M, Ohya Y, Sakima A, Yamazato M, Takishita S.
    Hypertens Res; 2007 Apr 24; 30(4):359-66. PubMed ID: 17541215
    [Abstract] [Full Text] [Related]

  • 17. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y, Hirooka Y, Sagara Y, Sunagawa K.
    Clin Exp Hypertens; 2007 Jan 24; 29(1):13-21. PubMed ID: 17190727
    [Abstract] [Full Text] [Related]

  • 18. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
    Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K.
    Am J Med Sci; 2007 Jun 24; 333(6):321-6. PubMed ID: 17570983
    [Abstract] [Full Text] [Related]

  • 19. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
    Nakamura K, Yamagishi S, Inoue H.
    Med Hypotheses; 2005 Jun 24; 65(1):155-7. PubMed ID: 15893134
    [Abstract] [Full Text] [Related]

  • 20. Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
    Ohmura C, Watada H, Shimizu T, Sakai K, Uchino H, Fujitani Y, Kanazawa A, Hirose T, Kawamori R.
    Endocr J; 2007 Dec 24; 54(5):805-11. PubMed ID: 17895576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.